Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Melanoma 37Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Neoplasms 9Colorectal Neoplasms 9Thyroid Carcinoma, Anaplastic 8Neoplasm Metastasis 6Multiple Myeloma 5Glioma 5Pancreatic Neoplasms 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Recurrence 3Prostatic Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Hematologic Neoplasms 3Ameloblastoma 3Skin Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neurofibroma, Plexiform 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Breast Neoplasms 2Astrocytoma 2

Interventions

Imatinib Mesylate 32regorafenib 9Sunitinib 9Laparoscopy 5Dasatinib 4Blood Specimen Collection 4pazopanib 3nilotinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Observation 3spartalizumab 2ripretinib 2envafolimab 2binimetinib 2apatinib 2Temozolomide 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2CTLA-4 Antigen 2Biopsy, Fine-Needle 2Biopsy 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Stromal Tumors × trametinib × Clear all
NCT02342600 2017-10-12

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Sarcoma Alliance for Research through Collaboration

Phase 2 Withdrawn
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡